0
0
In a groundbreaking move aimed at curbing the rise of sexually transmitted diseases (STDs), U.S. health officials have endorsed the use of an antibiotic as a morning-after pill. The Centers for Disease Control and Prevention (CDC) announced on Tuesday their recommendation for individuals at high risk of contracting chlamydia, gonorrhea, or syphilis to consider taking doxycycline shortly after unprotected sexual activity.
Described as a pivotal new prevention tool, this recommendation marks the first significant innovation in decades against STDs. Rates of these infections, particularly among gay and bisexual men, have seen persistent increases over the years, although recent data indicates stabilization in cases of chlamydia and gonorrhea since 2022.
The guideline specifically targets gay and bisexual men and transgender women who have had an STD within the past year and are at elevated risk of re-infection. While studies have shown efficacy in this group, the CDC emphasizes that evidence is currently insufficient to extend the recommendation to other demographics.
Known as doxy PEP (postexposure prophylaxis), the treatment involves a single 200 milligram dose of doxycycline, prescribed by doctors to be taken within three days of unprotected intercourse. Key updates from the draft guidelines released in October include clarifications on dosage frequency—restricted to once every 24 hours—and the recommendation for doctors to reassess the regimen with patients every three to six months.
The CDC’s endorsement underscores a strategic shift towards proactive measures in tackling STD transmission, reflecting a broader effort to innovate and adapt to evolving public health challenges.
